EKF Diagnostics Holdings plc is a global manufacturer of diagnostic instruments and reagents, specializing in point-of-care testing equipment. Founded in 1990 and headquartered in Cardiff, UK, the company offers a diverse range of products including hemoglobin analyzers like DiaSpect and Hemo Control, glucose and lactate analyzers such as Biosen C-Line and Lactate Scout 4, and various testing devices for pregnancy and other health indicators. Their product lineup also includes specialized analyzers for clinical applications, like the Altair 240 chemistry analyzer and the Uri-Trak 120 urine analyzer, as well as contract manufacturing services. EKF Diagnostics serves hospitals, laboratories, and government agencies directly, and distributes its products through a network of partners across Europe, the Middle East, the Americas, Asia, and Africa.
ADL Health is a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments.
Trellus Health
Seed Round in 2020
Trellus Health Inc. is a digital health company specializing in resilience-driven solutions for chronic conditions, particularly focusing on gastrointestinal disorders such as Crohn's Disease, Ulcerative Colitis, and Irritable Bowel Syndrome. Founded in 2020 and headquartered in White Plains, New York, with an additional office in Cardiff, United Kingdom, Trellus Health offers a telehealth-based multidisciplinary clinic that coordinates access to high-quality clinical care. Its connected care platform delivers whole-person care, encompassing both clinical and behavioral health services. By integrating evidence-based, clinically validated condition management programs with personalized coaching and user-friendly applications, Trellus Health aims to improve patient outcomes, enhance self-management, and promote better mental health while reducing healthcare costs for patients and employers.
DiaSpect Medical AB
Acquisition in 2014
DiaSpect Medical AB develops hemoglobin measurement systems.
Selah Genomics
Acquisition in 2014
Selah Genomics Inc. is a clinical diagnostic specialist based in Greenville, South Carolina, that provides advanced molecular and genomic diagnostic services to healthcare providers and the pharmaceutical industry in the United States. The company focuses on enhancing diagnostic testing services, particularly in women's health, and offers specialized tests for managing chronic conditions and personalized treatment plans for cancer based on individual tumor information. Selah Genomics provides a range of services, including next-generation sequencing, RNA sequencing, targeted and exome sequencing, companion diagnostics, and bioinformatics. Founded in 2006 and formerly known as Lab21 Inc., the company aims to improve patient outcomes through its comprehensive diagnostic solutions, which support early-stage drug development, clinical trials, and regulatory processes.
Separation Technology
Acquisition in 2014
Separation Technology Inc. provides centrifugation solutions to the laboratory marketplace.
360 Genomics
Acquisition in 2013
360 Genomics Ltd. develops molecular diagnostic technologies for the detection of mutations in key oncogenes.
Stanbio Laboratory, L.P.
Acquisition in 2011
tanbio Laboratory, L.P. manufactures medical devices and products for in-vitro diagnostic companies in the clinical laboratory market.
Argutus Medical
Acquisition in 2010
Argutus Medical specializes in developing and manufacturing advanced organ injury assays, focusing on tests for acute kidney injury and acute liver injury. The company creates enzyme-linked immunosorbent assays (ELISA) and lateral flow rapid test devices to detect nephrotoxicity and hepatotoxicity. Additionally, Argutus Medical offers a range of assays, including OxyDNA, which tests for oxidative DNA damage. Established in 2008 after separating from Biotrin International, Argutus Medical became part of EKF Diagnostics Holdings plc in 2010, enabling it to enhance its biomarker discovery and the development of innovative biomarker assays from its facility in Dublin, Ireland.
Quotient Diagnostics
Acquisition in 2010
Quotient Diagnostics Ltd. develops a testing technology for the diagnosis, treatment, and management of diabetes and associated diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.